Although there was variation in the ex-factory price between select cancer medications, in all cases the U.S. price per dose was higher than the average of the 11 other countries in this analysis. The four drugs with the highest U.S.-international price differentials were Ibrance, Afinitor, Sprycel and Zytiga. International prices from selected developed countries were compared to U.S. drug prices under Medicare Part D.
Price comparison U.S. vs. international per dose for select cancer drugs in 2018*
(in U.S. dollars)
Characteristic
U.S. price
Average (excluding U.S.) price
-
-
-
-
-
-
-
-
-
-
-
-
Exclusive Premium Statistic
To access all Premium Statistics, you need a paid Statista Account
* Cancer medication ex-factory prices, based on price data for 2018; collected from recognized price sources. Countries included in the analysis: United States, United Kingdom, Japan, Canada, Australia, Portugal, France, the Netherlands, Germany, Denmark, Sweden, and Switzerland. Comparison is with U.S. drug prices under Medicare Part D. Information on brand-name cancer medication provided by National Cancer Institute.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
US House of Representatives (Committee on Ways and Means). (September 23, 2019). Price comparison U.S. vs. international per dose for select cancer drugs in 2018* (in U.S. dollars) [Graph]. In Statista. Retrieved July 22, 2024, from https://www.statista.com/statistics/1134372/cancer-medication-exfactory-prices-average-vs-us/
US House of Representatives (Committee on Ways and Means). "Price comparison U.S. vs. international per dose for select cancer drugs in 2018* (in U.S. dollars)." Chart. September 23, 2019. Statista. Accessed July 22, 2024. https://www.statista.com/statistics/1134372/cancer-medication-exfactory-prices-average-vs-us/
US House of Representatives (Committee on Ways and Means). (2019). Price comparison U.S. vs. international per dose for select cancer drugs in 2018* (in U.S. dollars). Statista. Statista Inc.. Accessed: July 22, 2024. https://www.statista.com/statistics/1134372/cancer-medication-exfactory-prices-average-vs-us/
US House of Representatives (Committee on Ways and Means). "Price Comparison U.S. Vs. International per Dose for Select Cancer Drugs in 2018* (in U.S. Dollars)." Statista, Statista Inc., 23 Sep 2019, https://www.statista.com/statistics/1134372/cancer-medication-exfactory-prices-average-vs-us/
US House of Representatives (Committee on Ways and Means), Price comparison U.S. vs. international per dose for select cancer drugs in 2018* (in U.S. dollars) Statista, https://www.statista.com/statistics/1134372/cancer-medication-exfactory-prices-average-vs-us/ (last visited July 22, 2024)
Price comparison U.S. vs. international per dose for select cancer drugs in 2018* (in U.S. dollars) [Graph], US House of Representatives (Committee on Ways and Means), September 23, 2019. [Online]. Available: https://www.statista.com/statistics/1134372/cancer-medication-exfactory-prices-average-vs-us/